U.S. FDA Approves an Additional Indication for Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
RegulatoryapprovedCapvaxivePositive
AI Analysis
Summary
Merck announced FDA approval of an expanded indication for Capvaxive pneumococcal vaccine in children and adolescents aged 2-17 at increased risk for pneumococcal disease. This regulatory approval represents a label expansion for the vaccine.
Outcome Details
FDA approved expanded indication for Capvaxive in children and adolescents aged 2-17 at increased risk for pneumococcal disease
Importance:8/10
Sentiment:
0.85
FDA approvalindication expansionvaccinepediatricpneumococcal disease
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on June 18, 2026 3:06 AM